Editas Medicine names new chairman
13 April 2018 -

Editas Medicine, a genome editing company, has named James Mullen as its new chairman of the board of directors, it was reported yesterday.

Mullen has more than 30 years' experience leading biotechnology and pharmaceutical organisations on a global scale. Earlier, he has served as chief executive officer of Patheon. Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.

Katrine Bosley, president and chief executive officer of Editas Medicine, said, 'Jim is a renowned leader in the biotechnology industry with deep experience building global companies and guiding corporate strategy, and I am very pleased to welcome his as chairman of the board. Jim's extensive experience in driving excellence across R&D, commercialisation, manufacturing, business development and capital formation will be invaluable as we continue to build a genomic medicine leader and develop medicines for patients in the years to come.'